COAG (Hemab Therapeutics Holdings) Stock Based Compensation: $3.33 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $39.40
! 1 Warning Sign
View Full Analysis

What is Hemab Therapeutics Holdings Stock Based Compensation?

Hemab Therapeutics Holdings COAG -1.48% 11 Stock Based Compensation is $3.33 Mil as of Jun. 2026. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Hemab Therapeutics Holdings's Stock Based Compensation for the three months ended in Jun. 2026 was $2.02 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was $3.33 Mil.

Hemab Therapeutics Holdings Stock Based Compensation Related Terms

Hemab Therapeutics Holdings Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings Stock Based Compensation Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
Stock Based Compensation
1.91 2.01

Hemab Therapeutics Holdings Quarterly Data
Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial 0.46 0.49 0.00 1.32 2.02
COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.33 Mil.

What does a Stock Based Compensation of $3.33 Mil mean?
Hemab Therapeutics Holdings (COAG) has a Stock Based Compensation of $3.33 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Hemab Therapeutics Holdings and its competitors.
Is Hemab Therapeutics Holdings' Stock Based Compensation too high?
Hemab Therapeutics Holdings' current Stock Based Compensation is $3.33 Mil. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Stock Based Compensation compare to ADMA and VCEL?
Hemab Therapeutics Holdings' Stock Based Compensation of $3.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Hemab Therapeutics Holdings and its competitors. Hemab Therapeutics Holdings's current Stock Based Compensation is $3.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Stock Based Compensation of $3.33 Mil. The current Stock Based Compensation is $3.33 Mil. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Stock Based Compensation is $3.33 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.40
Price